Recent research regarding physical activity levels in heart failure patients shows a strong correlation with neurocognition and other more traditional functional assessments, such as the exercise capacity test. Accelerometer data from current implantable devices such as implantable cardiac defibrillators provides the opportunity to collect objective data as a heart failure patient goes about their daily activities. While increases in physical activity have face validity as a study objective in clinical trials, changes in summaries of the accelerometer recordings may function as a surrogate endpoint for traditional heart failure clinical outcomes. This talk will describe how surrogate endpoints are used in clinical trials and how their validity is assessed.
|
